Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds like you have been under a rock for four years.
while it is likely adxs pps is manipulated..it is certain there is little demand for shares by investors..otherwise the large percent volume increase in shares traded over the last month would not have brought the share price so low..why no demand for shares..small bio which has an explosive pipeline..but no detectable explosion since amgen..when it happens things change..you buy..if it happens you hold..its not happening you short..Since nothing has changed to indicate the multiple binary events will not occur i cannot help but believe when it happens..as for the funding..adxs seems to have little to no concern..and i will bet they are in a position to know..
adxs has one weakness..it has not commercialized anything..while on the cusp..it has not delivered..while there is much promising in the pipeline it is in the pipeline not on the market..with no revenue and a cooperative effort to take the share price down, the absence of demand for shares in this pre commercialized state..the bottom may not yet be in..and the manipulation far from over..sale of a franchise, partnering, petx getting approval..any of it could do it..only after the fact..
market memory is short..900 million already booked in future revenue from amgen, celene, stenhal..partnership with merck on psa construct..pending approval to market adxs her2 construct..potential licensing of it afterwards..partnership on hpv..cervical..head and neck..positive phase 2 anal trials..break thru in engineering LM to target unique genetic markers by cancer type..we are suppose to ignore all that because a few posters on here do ..lets concentrate on the massive short attack to find shares to cover..shares not available..millions of shares traded recently but shorts could only find 1.5 million to cover..where are all the other shares being bought and sold going..sadly for shorts the advice here isn't resonating..and news is coming..
October was the month shorts made all out war on adxs share price..a small biotech with less than 200 million market cap..nothing more than a grain of sand on the biotech beach..but the subject of intense and coordinated pps attack..there are dozens of small bios under 200 million market cap..why is adxs so special to receive this kind of attention from very powerful financial interests..10 million short shares trying to sabotage the commercialization of revolutionary cancer treatment..i have waited, i am waiting and i shall wait.
This p ps is tempting..not to mention warrants for 1.50..too much
shorts can cover during run-up on news or sell into it..i believe they have begun to cover with little success at these depressed pps levels. But adxs success is more about market share..EU is not a factor..current immuno treatments are way to expensive..there is a limit to what different countries can afford to pay to treat an individual citizen..but the US market is real target..adxs treatments can become SOC for hpv cervical subtypes..what's that worth..more than what it will cost to cover short interest no doubt..GOG is big factor and has already endorsed it with their own trials for hpv..the pps today is not the focus of long term investors ..just many of the posters..
one additional change pps..perhaps long investors expect too much too soon..now that limited commercialization seems around the corner..many just want to celebrate after the fact..news is possible on several fronts..its the occurrence rather than the likelihood i want to celebrate..
most expectations are numb.
shorts may have figured adxs wrong..thinking first dilution would be necessary..now thinking retail will sell from fear and dread..neither has happened..10million shares short and inelastic supply curve for shares..no chance to cover as a result of dilution..time running out and now wall street's attention on the overt shorting strategy..I'm hopeful..and like many other small retail investors did due diligence and been following this company a long time..hard to rattle us into selling as we are already motion sick from the bumpy ride.
seems to me this company has been moving towards the precipus of game changing cancer treatment with its programmable listeria vector that can target specific, unique markers on the cancer cell..the technology was worth 500million from amgen + full trial expenses, 300 million from selene, 10 million from stenhal and interest from merck for psa, astra for cervical, head and neck, bmy for cervical.. combine that with our new versatile business model towards big pharma and its own current p3 trials as well as the pending eu submission and a 160 million market cap seems undervalued to me..and while the HER2 for osteo in dogs will not result in game changing revenue it will result in lm product on the market..and commercial validation of the HER2 construct..with possible licensing revenue..
at these prices risk/reward ratio for adxs among informed share holders is heavily favored on reward with binary news imminent.. very difficult to shake 10 million + shares from current shareholders..but the shallow market demand for shares is disconcerting..shorts run unopposed ..yet selling seems non existent. there has been no capitulation..difficult to cover in this environment.I expect the ridiculous run up 2days ago followed by take down yesterday is in keeping with current efforts to find shares.
Shorts care more about covering or derailing adxs than they do about some puny fine from sec..what a worthless, toothless agency..but then again anyone's free to step in and buy at anytime..so maybe it is what it is..
these past 2 or 3 weeks has really been fascinating..watching the attack escalate all done with complete impunity.. respect
wow for a .17 stock the interest in it is amazing..long is the only side of this trade that makes any sense at all..considering risk/reward factor..
mc is 183 million..cash is 86 million..booked revenue..milestone payments with amgen and sellas 900 million. stenhal paying 10 million towards phase 3 aim2cerve. phase 2 trials with azn, merck, bmy..should i buy more LOL..?? proven efficacy and safety for variety of cancers as primary treatment and proven synergy with other immuno treatments..open for business with big pharma..variety of licensing deals..i know i'm just pumping with these basic facts while short sentiment is factual with generality and unproven innuendo..but "no one ever went broke under estimating the american public". being a relative novice to this world, i have had an intense lesson on segmented investment market supply/demand.
anders..i so wish this market reflected expected value in a positive way..but it has been oh to obvious for me that the opposite is more often the case with manipulations and illegal shorting designed to suppress true value..but it is what it is..you just have to know what you're getting into when you bet high risk high reward..its never easy. but at .17 a share we can be grateful stability is not baked in..and FDA approval will turn investor attention to vaccine tech for cancer treatments.
well said khaled..expresses many retail investors sentiment precisely
adxs LM platform allows the evolution of other targeted vaccines to improve efficacy..and it is inexpensive..who will want to license it for their very own use?
With shock and awe we have fallen..now hope is scared longs happily sell on price recovery..not the first time.
shorts may be edging us up for another attack, but doubt it..long term demand for shares has increased making things that more difficult to manage price decline..and combined with shorts now covering it reduces incrementally shares available for trading while demand is increasing..hence the rise in price..with any news that will become exponential with share demand up significantly and short covering continuing to reduce shares available..I am grateful to shorts as i am sure many investors are..they have and are giving us a window to buy at dirt cheap prices..i have doubled my own holding here since november 2014..and am grateful for these ops..market will eventually rule supreme..
Run up this morning then pull back followed by higher close..like yesterday
strategies, buy out predictions, timelines, 10 million short shares all suggest upward pressure on the share price..When people sell is their decision..I think everyone realizes the longer you hold this the better..but short term share price in the face of predictions here for longer term evaluations should see continued increase in share demand in a very low float environment..then catalyst with affirmation of LM platform's effectiveness,safety and cost advantage..disruptive technology breaking through the landscape..whats that worth..I am more than willing to buy more down here any chance i get..
lots of strategy advice involving selling or time lines..fact that conversation has switched to when..well things are very bright now..
seems the demand side may have improved somewhat..making manipulation more expensive..hence the increase in the number of sad longs..
as i remember this adxs responded to EU request for more info.several months ago..and that EU had invited adxs to apply as they were enthusiastic about providing an option to those who have no option..
shorts beginning to cover perhaps..and trying to keep it low key for as long as possible..also probably increased investor interest after kite sale adding upward pressure..one can hope. Plus the phase i starting with amgen for mine..i believe a milestone payment is due..not public how much..things are beginning to happen..
10 million shorts trying yo make a case for dilution..lmao..no shxt.
I'm skeptical about all the hype..seen this before..setting high expectations then not met shorts bring price down..common tactic..wait and see
thank you..sounds like good advice..
nice to read different perspectives from the usual b/o s/p daily focus, as these seem very seasoned and experienced commentators..long but without an agenda. It seems to me the LM platform is being validated every day with the advent of phase 1, phase 2, phase 3 studies as an effective treatment for a variety of hpv, her2 and now prostate cancers..Immediate approval is about providing life expectation to those who have none..
The kite 11 billion purchase should underscore the validity of immune therapies..thinking that a alone may increase investor demand for small, promising and overlooked bios in this sector.. the only cure for 10 million short shares..
don't you think bots/algos have begun pushing it up..even the most oblivious can see whats at stake here..it will be a bumpy ride..
Don't worry about buyout numbers here..they are as irrelevant as they are scripted..bought and paid..amusing though
Very interesting article..hard to see this car-t treatment being widely used even in developed countries..forget about 3rd world..adxs on the other hand is extremely cost competitive even reachable in 3rd world for treatment..I like my investment..and mist admit it's thanks to shorts I have been able to acquire so much over the years
adxs LM platform is the source for her-2 cancers, prostate, hpv cancers, mine..the efficacy of these therapies being proven..her2 for the long awaited osteo in dogs, hpv for head and neck, anal and cervical, and recently prostate with promising results from phase i..additionally adxs is developing expertise on markers that predict treatment efficacy for their products.
ignateius..learned some things following this thread..difficult to access the value of a programmable vaccine environment..
Short adxs like sleeping under a guiloteen.
Yes sir
So how many approved treatments does kite have